TheFiscalFinder
● Single award · contract

COVID-19: Monoclonal Antibody (Mab) Therapeutic Sotrovimab

A single federal award, with both ends of the trail linked.
$279.9M
total award value
2021
action date
8 mo
period
W58P0521C0008
PIID
Agency ›
Department of Defense
✓ from source
awarded→$279.9M
Recipient ›
Glaxosmithkline, LLC
✓ from source
performed in→
State ›
North Carolina
✓ from source

Description

:COVID-19: Monoclonal Antibody (Mab) Therapeutic Sotrovimab

Awarding agencyDepartment of Defense →
RecipientGlaxosmithkline, LLC →
Place of performanceNorth Carolina →
CategoryNAICS 325412PSC 6505
Competed?Not recorded✓ from source
Total (exact)$279,862,800

More awards to Glaxosmithkline, LLC

COVID-19: Sotrovimab Monoclonal Andtibodies
awarded 2021$1.6B
Vacines for Children
awarded 2017$682.2M
Vaccine for Children (Vfc) 2014
awarded 2014$602M
Vacccine for Children 2012
awarded 2012$554.8M
Glaxosmithkline Adjuvant AS03
awarded 2020$335.6M
All awards to this recipient →

More from Department of Defense

Contract HT940216C0001
awarded 2016$51.3B
LRIP Lot 12 Advance Acquisition Contract
awarded 2017$35.1B
SSN 802 and 803 Long Lead Time Material
awarded 2017$34.9B
Contract N0001902C3002
awarded 2001$34.2B
KC-X Modernization Program
awarded 2011$32B
All awards from this agency →
🔎
Why the labels? The graph is only worth anything if the links are trusted. Facts taken straight from a federal filing are ✓ from source; figures we calculate are ≈ computed; links we infer (corporate parents, districts, competitors, connections between records) are ≈ inferred, worded carefully, never asserted as fact and never a claim that one thing caused another. Spot an error? Tell us.